<img height="1" width="1" src="https://www.facebook.com/tr?id=1582471781774081&amp;ev=PageView &amp;noscript=1">
  • Menu
  • crown-logo-symbol-1-400x551

Find it Quickly

Get Started

Select the option that best describes what you are looking for

  • Services
  • Models
  • Scientific Information

Search Here For Services

Click Here to Start Over

Search Here For Models

Click Here to Start Over

Search Here For Scientific Information

Click Here to Start Over

In Vitro

Boost oncology drug discovery with XenoBase®, featuring the largest cell line selection and exclusive 3D organoid models. Benefit from OrganoidXplore™ and OmniScreen™ for rapid, in-depth analysis.

Learn More

In Vivo

Enhance drug development with our validated in vivo models, in vitro/ex vivo assays, and in silico modeling. Tailored solutions to optimize your candidates.

Learn More


Experience ISO-certified biobanking quality. Access top biospecimens from a global clinical network, annotated by experts for precise research.

Learn More

Biomarkers and Bioanalysis

Leverage our global labs and 150+ scientists for fast, tailored project execution. Benefit from our expertise, cutting-edge tech, and validated workflows for reliable data outcomes.

Learn More

Data Science and Bioinformatics

Harness your data and discover biomarkers with our top bioinformatics expertise. Maximize data value and gain critical insights to accelerate drug discovery and elevate projects.

Learn More


Accelerate innovative cancer treatments with our advanced models and precise drug screening for KRAS mutations, efficiently turning insights into clinical breakthroughs.

Learn More


Advance translational pharmacology with our diverse pre-clinical models, robust assays, and data science-driven biomarker analysis, multi-omics, and spatial biology.

Learn More

Drug Resistance

Our suite integrates preclinical solutions, bioanalytical read-outs, and multi-omics to uncover drug resistance markers and expedite discovery with our unique four-step strategy.

Learn More

Patient Tissue

Enhance treatments with our human tumor and mouse models, including xenografts and organoids, for accurate cancer biology representation.

Learn More


Apply the most appropriate in silico framework to your pharmacology data or historical datasets to elevate your study design and analysis, and to improve your chances of clinical success.

Learn More

Biomarker Analysis

Integrate advanced statistics into your drug development projects to gain significant biological insight into your therapeutic candidate, with our expert team of bioinformaticians.

Learn More


Accelerate your discoveries with our reliable CRISPR solutions. Our global CRISPR licenses cover an integrated drug discovery platform for in vitro and in vivo efficacy studies.

Learn More


Rely on our experienced genomics services to deliver high quality, interpretable results using highly sensitive PCR-based, real-time PCR, and NGS technologies and advanced data analytics.

Learn More

In Vitro High Content Imaging

Gain more insights into tumor growth and disease progression by leveraging our 2D and 3D fluorescence optical imaging.

Learn More

Mass Spectrometry-based Proteomics

Next-generation ion mobility mass spectrometry (MS)-based proteomics services available globally to help meet your study needs.

Learn More

Ex Vivo Patient Tissue

Gain better insight into the phenotypic response of your therapeutic candidate in organoids and ex vivo patient tissue.

Learn More

Spatial Multi-Omics Analysis

Certified CRO services with NanoString GeoMx Digital Spatial Profiling.

Learn More

Biomarker Discovery

De-risk your drug development with early identification of candidate biomarkers and utilize our biomarker discovery services to optimize clinical trial design.

Learn More

DMPK Services

Rapidly evaluate your molecule’s pharmaceutical and safety properties with our in vivo drug metabolism and pharmacokinetic (DMPK) services to select the most robust drug formulations.

Learn More

Efficacy Testing

Explore how the novel HuGEMM™ and HuCELL™ platforms can assess the efficacy of your molecule and accelerate your immuno-oncology drug discovery programs.

Learn More

Laboratory Services

Employ cutting-edge multi-omics methods to obtain accurate and comprehensive data for optimal data-based decisions.

Learn More

Pharmacology & Bioanalytical Services

Leverage our suite of structural biology services including, recombinant protein expression and protein crystallography, and target validation services including RNAi.

Learn More


Find the most appropriate screen to accelerate your drug development: discover in vivo screens with MuScreen™ and in vitro cell line screening with OmniScreen™.

Learn More


Carry out safety pharmacology studies as standalone assessments or embedded within our overall toxicological profiling to assess cardiovascular, metabolic and renal/urinary systems.

Learn More

Our Company

Global CRO in California, USA offering preclinical and translational oncology platforms with high-quality in vivo, in vitro, and ex vivo models.

Learn More

Our Purpose

Learn more about the impact we make through our scientific talent, high-quality standards, and innovation.

Learn More

Our Responsibility

We build a sustainable future by supporting employee growth, fostering leadership, and exceeding customer needs. Our values focus on innovation, social responsibility, and community well-being.

Learn More

Meet Our Leadership Team

We build a sustainable future by fostering leadership, employee growth, and exceeding customer needs with innovation and social responsibility.

Learn More

Scientific Advisory Board

Our Scientific Advisory Board of experts shapes our strategy and ensures top scientific standards in research and development.

Learn More

News & Events

Stay updated with Crown Bioscience's latest news, achievements, and announcements. Check our schedule for upcoming events and plan your visit.

Learn More

Career Opportunities

Join us for a fast-paced career addressing life science needs with innovative technologies. Thrive in a respectful, growth-focused environment.

Learn More

Scientific Publications

Access our latest scientific research and peer-reviewed articles. Discover cutting-edge findings and insights driving innovation and excellence in bioscience.

Learn More


Discover valuable insights and curated materials to support your R&D efforts. Explore the latest trends, innovations, and expertly curated content in bioscience.

Learn More


Explore our blogs for the latest insights, research breakthroughs, and industry trends. Stay educated with expert perspectives and in-depth articles driving innovation in bioscience.

Learn More

  • Platforms
  • Target Solutions
  • Technologies
  • Service Types

Evaluating Immunotherapy Mechanism of Action with Immune Cell Lineage-Specific DTR Models

Diphtheria Toxin Receptor (DTR) ModelsExplore how transgenic diphtheria toxin receptor (DTR) preclinical models are used to better understand immunotherapy mechanisms of action and response.

Using Immune Cell Depletion and Diphtheria Toxin Receptor (DTR) Mouse Models for Immunotherapy Studies

To fully understand (and improve) the response to immunotherapy, and the attrition rate of new agents, a two-pronged approach is needed. Firstly, more predictive and robust preclinical models and methods are needed, to minimize preclinical translational failures in immuno-oncology. Secondly, a deeper understanding of immunological mechanisms of action and biomarker strategies is also needed to minimize immunotherapy clinical failure.

To determine the functional contributions of different cellular components of the immune system, preclinical models have been established where distinct immune cells can be depleted. One important model to selectively deplete cell populations is the diphtheria toxin receptor (DTR) mouse model.

What is Immune Cell Depletion?

Immune cell depletion is a powerful method for determining the functional contributions of different immune system components. The technique is particularly useful for studying underlying mechanisms of cancer immunotherapies, since they often work through multiple mechanisms mediated by different immune cell subsets.

Many preclinical models, such as antibody-mediated approaches and transgenic DTR animals, have been established to deplete distinct immune cells. The use of cytotoxic antibodies for immune depletion is thought to lead to deletion efficiencies in the range of 70–90% (which is dependent on the antibody, cell type, etc.) and various limitations with this approach have been described.

Transgenic DTR strains have been playing an increasingly important role in studies requiring the targeted depletion of specific immune cell populations. These models are particularly useful for depleting lineages that lack cell surface markers typically targeted by monoclonal antibodies.

DTR Mouse Lines for Immune Cell Depletion Studies

Specific immune cell lineages can be depleted using conditional transgenic DTR mouse models, which represent a simple and sensitive method for achieving immune cell lineage ablation. In general, these models are engineered to express DTR downstream of specific cell lineage promoters. Then, upon exposure to DT (which is a strong inhibitor of protein synthesis in growing and non-growing cells) cellular death of the target cell expressing the DTR is induced.

Cre-inducible DTR transgenic mice (iDTR), in which the Cre-mediated excision of a STOP cassette renders cells sensitive to DT, have also been generated and shown to efficiently ablate immune cell lineages after DT exposure.

Some of the existing DTR mouse lines for depleting the most common immune cell lineages include:


FoxP3 is important for T regulatory (Treg) cell lineage specification and function in both mice and humans. Foxp3-DTR mice express knocked-in human DTR and EGFP from the Foxp3 locus with no disruption of endogenous Foxp3 gene expression. These mice are used to deplete Treg cells after administration of DT.

Liu et al. (2016) used this strain to generate tumor-bearing mice with prolonged Treg depletion. The models were used to assess the mechanism, safety, and efficacy of transient Treg depletion in combination with monoclonal antibodies targeting the immunomodulatory receptors PD-1, TIM-3, or CD137. The model effectively recapitulated the spectrum of antitumor responses, as well as grade 3/4 immune-related adverse events (irAEs) that are known to occur in a high proportion of combination immunotherapy-treated patients.


The CD4-Cre mouse strain is crossed with the Cre-inducible DTR mouse to efficiently generate animals that are depleted of T cells after DT administration.


The CD19-Cre mouse strain is crossed with the Cre-inducible DTR mouse to efficiently generate animals that are depleted of B cells after DT administration.


Cd8α is a cell lineage marker for cytotoxic T cells. Cd8α-DTR mice express knocked-in human DTR and EGFP from the Cd8α locus with no disruption of endogenous Cd8α gene expression. These mice are useful for ablation and visualization of CD8+ T cells.

Dendritic Cells (DCs):

Several DTR-based mouse strains have been generated to eliminate DCs and subsets of DCs. For instance, the CD11c-DTR mouse uses the CD11c promoter to guide the DTR expression to DC populations, and when exposed to DT, DC populations are depleted. Other strains include the Itgax-DOC mouse and the Zbtb46-DTR mouse, with other models also available for depleting subsets of DCs.

Several limitations have been noted for the CD11c-DTR mouse, including the toxicity of repeated DT administrations in these animals and the expression of CD11c by non-DCs (e.g. marginal zone macrophages, alveolar macrophages, activated CD8 T cells) and the resulting depletion of these cells after DT administration. Ablation of these other cell types can potentially complicate analyses with this strain.

Natural Killer (NK) cells

NKp46 is selectively expressed by all NK cells (CD49b+ and CD49b) across multiple species (human, mouse, non-human primate). To achieve selective depletion of NK cells, the NKp46 promoter was used to generate transgenic mice with a NK cell-specific gene expression of DTR, where each DT injection depletes NK cells for a minimum of seven days. This model is effective for preclinical studies looking to evaluate the role of NK cells.


CD11b-DTR mice express human DTR under the control of the human CD11b promoter. A relatively low dose of DT results in macrophage ablation with minimal damage to other mouse cells since the human DTR has a much higher sensitivity to DT than the mouse DTR. While CD11b is expressed on several myeloid lineage cell populations (e.g. macrophages, monocytes, and neutrophils), the administration of DT does not deplete neutrophils.

In addition, other mouse strains, such as the CD169-DTR and CD206-DTR strains, provide ablation of specific macrophage subsets, and these strains may also differentially deplete other myeloid lineages as compared to the CD11b-DTR mouse. These models are effective for preclinical studies looking to evaluate the role of specific macrophage populations.


Diphtheria toxin receptor-based transgenic models represent a very efficient and powerful immune cell depletion option, used to better understand and improve the response to immunotherapy. Prior to selecting a DTR model for immune cell lineage depletion studies, you should consider the goal of your study and the relative advantages and disadvantages of the various DTR transgenic lines discussed here.

Related Posts